Safety and Effectiveness of Combination Rituximab and Cyclophosphamide Therapy for Treating Pediatric Patients With Severe Manifestations of Rheumatic Disease.

ABSTRACT:

Objective

Current practice guidelines recommend the use of either rituximab (RTX) or cyclophosphamide (CYC) for the treatment of severe manifestations of systemic vasculitis or connective tissue disease. Few studies have evaluated safety and efficacy outcomes of combination therapy with RTX and CYC. We undertook this study to evaluate outcomes in the first 12 months of RTX/CYC combination therapy in pediatric patients with rheumatic disease.

Methods

Patients who received combination RTX/CYC therapy for a rheumatic disease between January 2020 and February 2023 at a single center were included. The primary outcomes of interest were death and infection requiring hospitalization within 12 months of combination therapy. Secondary outcomes included change in serologic lupus disea

SUBMITTER: Rife E 

PROVIDER: S-EPMC12436411 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature